

**Increased Risk of Herpes Zoster with Tofacitinib Treatment in Korean Patients with Rheumatoid Arthritis: A Single-Center
Prospective Study**

Yeo-Jin Song^{1,2}, Soo-Kyung Cho^{1,2}, Hyoungyoung Kim^{1,2}, Hye Won Kim², Eunwoo Nam², Ja-Young Jeon³, Hyun-Jeong Yoo³, Chan-Bum Choi^{1,2}, Tae-Hwan Kim^{1,2}, Jae-Bum Jun^{1,2}, Sang-Cheol Bae^{1,2}, Dae Hyun Yoo^{1,2}, Yoon-Kyoung Sung^{1,2}

¹ Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

² Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea

³ Pfizer Pharmaceuticals Korea Ltd., Seoul, Republic of Korea

Supplementary Table 1. Incidence of HZ in RA patients treated with tofacitinib versus those treated with TNFi between March 2017 and May 2021

	Tofacitinib		TNFi		Incidence rate ratio ^b (95% CI)	<i>P</i>
	Case	Incidence rate ^a	Case	Incidence rate ^a		
<i>Before IPTW</i>						
Total observation period	20	6.03	9	2.57	2.35 (1.07–5.16)	0.033
Within 12 months	12	7.39	4	2.37	3.12 (1.01–9.66)	0.049
<i>After IPTW</i>						
Total observation period	20	6.03	2	0.94	6.45 (1.40–29.75)	0.017
Within 12 months	12	7.39	1	0.81	9.17 (1.08–77.73)	0.042

HZ herpes zoster, *RA* rheumatoid arthritis, *TNFi* tumor necrosis factor inhibitor, *CI* confidence interval, *IPTW* inverse probability of treatment weighting.

^a Incidence rate was calculated as cases per 100 person-years.

^b Incidence rate ratio and 95% CI were estimated using a Poisson regression model.